Immunity 101: The Quick Course
Introductory content goes here…
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Mauris placerat ullamcorper sem eu sodales. Praesent suscipit mauris nec augue bibendum, ut consequat massa sodales. Proin et lacus enim. Vivamus vulputate luctus ultrices. Quisque consequat porttitor fringilla. Mauris vitae nulla porttitor, gravida diam et, egestas mauris. Mauris convallis metus at urna rutrum, eget hendrerit metus porttitor. Maecenas posuere lorem rhoncus nisi eleifend mollis.
Web Tip: This has the potential to change everything and give us freedom like that already enjoyed by those vaccinated who have a normal immune system.
Related Articles
Lower COVID-19 Mortality and Hospitalization Rates in CLL and MBL: Do Repeated Vaccination and Anti-Viral Therapy Help?
The overall hospitalization rate was only 5.2%, and the mortality rate (MR) was 1.3% in COVID-19-infected patients with chronic lymphocytic leukemia (CLL) and monoclonal B-cell lymphocytosis (MBL), a CLL precursor.
CLL Society’s COVID-19 Update for the Week of September 18, 2023
It’s been a while since our last COVID-19 Update in May when the end of the public health emergency was declared, resulting in a severe lack of funding for tracking the disease metrics
New COVID-19 Vaccine Clinical Trial Specifically for Those with CLL and Other Blood Cancers
Now there is a new trial (SUPERNOVA) of an updated mix of monoclonal antibodies that hopes to provide durable protection against present and future variants of concerns.
Nurses Note: The Importance of Advocating for Your Safety in Healthcare Settings
We have for a very long time known that those with CLL / SLL are at risk for having difficulty fighting off infections
Study Understanding Pre-Exposure Prophylaxis of Novel Antibodies (SUPERNOVA)
Now there is a new trial (SUPERNOVA) of an updated mix of monoclonal antibodies that hopes to provide durable protection against present and future variants of concerns.
FDA Approved Paxlovid for Treatment of COVID-19
Paxlovid is now fully approved for treating mild-to-moderate COVID-19 in adults at high risk for progression to severe COVID-19.
RECENT NEWS
When appropriate, the CLL Society will be posting updates and background information on the present Coronavirus pandemic focusing on reliable primary sources of information and avoiding most of the news that is not directly from reliable medical experts or government and world health agencies.
